cytarabine

P2, N=25, Not yet recruiting, First Affiliated Hospital of Zhejiang University

P2, N=60, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

DDX6 KO leads to rapid PB dissolution and release of PB-enriched mRNAs, such as BCAT1, into the cytosol, where these transcripts undergo degradation. By reducing BCAT1 levels, DDX6 KO reprograms amino acid metabolism and sensitizes AML cells to cytarabine chemotherapy.

P2, N=80, Recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

P2/3, N=80, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.

Induction chemotherapy (cytarabine and idarubicin) initially achieved remission, but subsequent relapses led to the use of venetoclax and 5-azacytidine, which again resulted in remission. This is the first report that molecularly characterizes the HMBOX1::JAK2 fusion in a de novo AML patient. The identification of this novel alteration adds to the growing and heterogeneous molecular landscape of AML and suggests a potential new avenue for targeted therapy.

Although pleural myeloid sarcoma is extremely rare, it must be included in the differential diagnosis for unexplained solid pleural masses, particularly when accompanied by pleural effusion. Upon diagnosis, comprehensive staging investigations, including bone marrow biopsy and flow cytometry, must be performed immediately. The successful management of such complex cases relies on the close collaboration of a multidisciplinary team, including radiologists, pathologists, hematologists, and thoracic surgeons. Radiologists identify atypical imaging features, pathologists confirm the diagnosis through precise immunophenotyping, and ultimately, hematologists formulate and execute the correct treatment plan.

P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

P=N/A, N=80, Recruiting, Sohag University

The impact of Necrostatin-1s (Nec-1s) and cytarabine on neuronal degeneration was evaluated, along with a comparison of the effects of tamoxifen dissolved in different plant oils on lineage tracing in Sox10/iCreERT2; tdTomato mice, as well as on neuronal degeneration in NTN-1 cKO mice. These results suggest that, under pathological conditions, Cre recombinase can transfer from oligodendroglia to neurons, a process triggered by neuronal stress. This highlights the need for careful consideration in using Cre-loxP lineage tracing and gene-editing methods involving oligodendrocyte lineage cells and neurons.

Although the European LeukemiaNet (ELN) classifications (2017, 2022) for AML have been used to stratify outcomes for patients receiving intensive chemotherapy, application to patients receiving less intensive therapy, like azacitidine plus venetoclax, has been less satisfactory. Overall, these data support the importance of molecular sub-classification in defining treatment outcomes to venetoclax-based therapies. NCT02287233; NCT03069352.

Not available.